Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Dallas, TX

98 studies for Breast Cancer are recruiting at 170 sites within 50 miles of Dallas, Texas, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Dallas.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Dallas

Showing the 50 nearest of 98 studies.
  1. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology - Presbyterian (Dallas, TX); Texas Oncology-Baylor Charles A. Sammons Cancer Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  2. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UT Southwestern Medical Center at Redbird (Dallas, TX); University Of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    NCT05208762

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UT Southwestern Medical Center - Redbird (Dallas, TX); Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  4. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Parkland Memorial Hospital (Dallas, TX); UT Southwestern Simmons Cancer Center - RedBird (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  5. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Parkland Health & Hospital System ( Site 0096) (Dallas, TX); Texas Oncology - DFW ( Site 8000) (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    NCT06312176

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Parkland Health and Hospital System ( Site 0069) (Dallas, TX); Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  7. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology - DFW ( Site 8009) (Dallas, TX); UT Southwestern ( Site 0092) (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  8. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UT Southwestern/Simmons Cancer Center-Dallas (Dallas, TX); UT Southwestern Clinical Center at Richardson/Plano (Richardson, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  9. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Texas Oncology - Baylor Charles A. Sammons Cancer Center (Dallas, TX); Texas Oncology - Dallas Presbyterian Hospital (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  10. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    NCT07085767

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Trial Site (Dallas, TX); Clinical Trial Site (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  11. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest sites: UT Southwestern Medical Center (Dallas, TX); Texas Oncology (Plano, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  12. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest sites: UT Southwest Simmons Cancer Center (Dallas, TX); Texas Oncology (Bedford, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  13. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Mary Crowley Cancer Research (Dallas, TX); USOR Texas Oncology (Fort Worth, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  14. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    NCT05735080

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Next Oncology (Dallas, TX); UTSW Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  15. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    NCT05768139

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology-Baylor Charles A. Sammons Cancer Center (Dallas, TX); University of Texas Southwestern (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Mary Crowley Cancer Research (Dallas, TX); Texas Oncology-Baylor Charles A. Sammons Cancer Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology - DFW (Dallas, TX); Texas Oncology-Northeast Texas (Allen, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    NCT06625775

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI at Mary Crowley (Dallas, TX); University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Baylor University Medical Center (Dallas, TX); Mary Crowley Cancer Research (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    NCT06827236

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Baylor Scott & White Research Institute -Texas Oncology (Dallas, TX); UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology DFW (Dallas, TX); University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    NCT07060807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology - DFW ( Site 8003) (Dallas, TX); JPS Health Network ( Site 0067) (Fort Worth, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    NCT07102381

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Texas Oncology DFW (Dallas, TX); The University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USO - Texas Oncology (Dallas, TX); UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

    NCT07540572

    • Phase 1
    • Ages 18 to 99 years
    • Sex: All

    Nearest sites: NEXT Texas LLC - Dallas (Dallas, TX); START Dallas Fort Worth, LLC (Fort Worth, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. GammaPod Registry and Quality of Life Nomogram

    NCT03562273

    • Observational
    • Ages 18 years and older
    • Sex: Female

    Nearest site: UTSouthwestern (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. Converting HR+ Breast Cancer Into an Individualized Vaccine

    NCT03804944

    • Phase 2
    • Ages 18 to 90 years
    • Sex: Female

    Nearest site: UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

    NCT04265872

    • Early Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

    NCT04373564

    • Phase 4
    • Ages 18 to 64 years
    • Sex: All

    Nearest site: UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

    NCT04614194

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

    NCT05029999

    • Phase 1
    • Ages 18 to 99 years
    • Sex: All

    Nearest site: UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    NCT05059444

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    NCT05216432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

    NCT05245812

    • Interventional
    • Ages 18 to 80 years
    • Sex: Female

    Nearest site: UT Southwestern (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    NCT05377996

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Texas Oncology, P.A. (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

    NCT05490472

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Mary Crowley Cancer Research (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    NCT05503797

    • Phase 2
    • Ages 8 years and older
    • Sex: All

    Nearest site: Baylor Scott & White Research Institute (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest site: UT Southwestern/Simmons Cancer Center-Dallas (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    NCT05573126

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Texas Oncology Baylor University Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. Susan G. Komen's ShareForCures

    NCT05654246

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Susan G. Komen (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

    NCT05693766

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: UT Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

    NCT05746897

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: NEXT Oncology, Dallas (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

    NCT05748834

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Texas Oncology- DFW (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    NCT05768932

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Baylor University Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. Study of AVZO-021 in Patients With Advanced Solid Tumors

    NCT05867251

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Avenzo Therapeutics Recruiting Site (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

    NCT05919108

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Texas, Southwestern (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

    NCT05941507

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Mary Crowley Cancer Research (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Neratinib in Combination With Ruxolitinib in Patients With mTNBC

    NCT06008275

    • Early Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

    NCT06085833

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Texas Southwestern Medical Center (Dallas, TX)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.